Member Info for TheDogFarther

Dr Deo, you are correct. There are other parameters to take into account. But there are parameters that we dont know. For example , there may be a bout of Flu going around at the FDA or the local football team winning the conference table, resulting in days off due to too much celebrating. Whatever the case, each day that passes the odds move in HEMOs way. The original statement remains correct. Tick, Tick Tock, the Shorters are now on the HEMO clock.

Haywain ,the bet was when does the RNS land. There are 15 working days left from the original 30 days the FDA had to reply.

The FDA must reply, so clearly the chances of a reply are 100%. Each day mathematically has an equal chance of seeing an RNS .Therefor on day 15 100 divided by 15 is 6.6%. say no RNS today , then tomorrows chance increases to 7.1%.

Therefor , Everyday the Odds move further HEMOs way.

Best thing to do Blast. You started it , but didnt have the intellect to finish it.

Basically, he cant be bothered to post anything of any real interest .

"Zzzzzzzzz 🙄"

My guess is 15 work days , where you can post an RNS re the FDA reply.

That means tomorrow has a 6.6% chance.

Rubber Jonny, if you don't understand why, you don't understand maths.

Anyone know, how many business days the FDA has left to give the answer ?. I want to work out the increasing probability of the event on a daily basis.

Im predicting 4p by Friday afternoon. Everyday without the RNS gets more exciting.

So we are led to believe that the IG Shorts went from 8% to zero and the the next day back to 8. Doesn't sound right to me. Is Fujitsu in charge of IGs IT system.

I have been reliably informed , that the major Shorter here is called Paddy, Paddy Pantsdown.

Yes, 4p target before the game changing RNS.

3%.

No mr jinx. There is something called research. Here is a bit more for you.

There are over 600,000 cancer deaths in the US alone. £% of them are attributable to -non-hodgkin-lymphoma. Thats over 20,000 people every year. If half of those were able to access HEMOs treatment ( and of course it was proven to work, then at a $10,000 cost per patient ( well below the current cost of treatment) then that would bring in approximately $100,000,000 revenue per year.

In answer to a further highly intellectual comment from you mr Jinz, the Global -non-hodgkin-lymphoma-market will be worth over $16 Billion dollars by 2031. HEMOs Chimeric Bait Receptor is a promising treatment of the illness. I wouldn't be at all surprised if Major Pharma's were keeping a very close eye on HEMO, at this very moment.

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that its Chimeric Bait Receptor ("CBR") platform can potentially be used in the treatment of cancers, in addition to the viral diseases extensively reported by the Company to date.

The Company has demonstrated that human macrophages, a type of immune cells, programmed with a purpose designed CBR, were able to eliminate Non-Hodgkin Lymphoma ("NHL") derived cells with high efficiency in vitro. This result suggests that the Company may be able to develop an efficient treatment for people suffering from relapsed and/or refractory stage III/IV metastasized NHL. In addition, based on data derived from its testing of CBR in connection with NHL, the Company has reason to believe that the newly designed CBR construct can be adapted to target several solid tumours such as epithelial ovarian cancer as well as certain carcinomas.

What ,so CBR can also be used in the treatment of Cancers ( Yes Plural).

Googled it.I am still laughing.

Again from the half year report.

Meanwhile, we have continued to work on our other major product candidates, in particular our Chimeric Bait Receptor ("CBR") platform which, as shareholders are aware, is focussed on developing a new approach which we believe will provide effective cures for a wide range - indeed perhaps the full range - of viral infections, including diseases for which no cures are available at present. In the wake of the COVID-19 pandemic, and facing global threats of biological warfare and the fast spreading of pandemics from previously unknown diseases, the need for proactive solutions against future infectious agents has become clear. To address this imminent threat, our CBR immunotherapy is designed to prevent and combat infection by any known or emerging virus.

https://www.lse.co.uk/rns/HEMO/half-year-report-e2e2nv4g7cdep0k.html

Ahh Mr Jinx. The intelligent listen to the intelligent. That's what makes them intelligent. I note your comment as see that we don't have to worry about you falling into that category.

"Oh ffs, get a room with her and leave us out of it."

I did, i think you will find, say if he has time. Im very interested in his view on the HEMO product production line. So far he has been right on CAT-T. I would value his thoughts on other products

If JHFH has time, i think that many on here would like to see his views on a time line , with other HEMO products and the route to a £300 million Market Cap.

An Intra day RNS is always possible. Imagine if you have sold and it jumps to 6p.